Posted by Paige | Posted in Cystic Fibrosis News | Posted on 04-02-2010
This week, we gained important new ground in our work to advance the development of new cystic fibrosis treatments.
VX-809, a potential CF drug developed by Vertex Pharmaceuticals, showed encouraging results in a preliminary Phase 2a clinical trial. VX-809 is one of the first investigational drugs aimed at treating the underlying causes of CF.
The oral therapy was tested in patient volunteers who have the most common cystic fibrosis mutation, Delta F508.
Results from the trial showed VX-809 was well-tolerated and, in a subset of CF patients, reduced sweat chloride levels ? a key indicator of CF.
VX-809 is the direct result of one of the Foundation?s largest investments in drug development. This gives us confidence that our innovative approach to science leads to progress.
Without your support, this milestone would simply not be possible. Your contributions help us build hope for the future and continue to advance vital cystic fibrosis research.
If you have CF, you can also help by participating in a clinical trial. Visit the Foundation?s Web site to learn more about clinical trials and to find out how you can get involved.
Thank you for your commitment to the fight against CF. Together, we are making a difference!
